Arcellx (NASDAQ:ACLX) Insider Rami Elghandour Sells 89,916 Shares

Arcellx, Inc. (NASDAQ:ACLX) insider Rami Elghandour sold 89,916 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the completion of the sale, the insider directly owned 276,051 shares of the company’s stock, valued at $31,447,729.92. This trade represents a 24.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Arcellx Stock Performance

NASDAQ:ACLX traded down $0.09 during trading hours on Friday, reaching $113.79. The company’s stock had a trading volume of 2,863,723 shares, compared to its average volume of 4,178,776. The firm has a market capitalization of $6.58 billion, a price-to-earnings ratio of -28.95 and a beta of 0.36. The firm has a 50-day simple moving average of $71.81 and a 200-day simple moving average of $76.22. Arcellx, Inc. has a 1 year low of $47.86 and a 1 year high of $114.26.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ACLX shares. Robert W. Baird restated a “neutral” rating and set a $115.00 price target (up from $106.00) on shares of Arcellx in a research report on Monday. Canaccord Genuity Group set a $115.00 target price on shares of Arcellx in a research note on Monday. Wells Fargo & Company lowered shares of Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 price target for the company. in a report on Monday. Citigroup cut shares of Arcellx from a “buy” rating to a “neutral” rating and increased their price target for the company from $110.00 to $115.00 in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arcellx in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Arcellx currently has a consensus rating of “Hold” and an average price target of $111.87.

Key Headlines Impacting Arcellx

Here are the key news stories impacting Arcellx this week:

• Neutral Sentiment: Reported short-interest data shows zero shares and a 0.0 days-to-cover figure for late February; this looks like a data or reporting anomaly rather than a meaningful change in market positioning — monitor for corrected filings or confirmations from exchanges.
• Neutral Sentiment: HC Wainwright published an FY2030 earnings forecast for Arcellx; long-range model updates can influence valuation assumptions but are less likely to move the stock immediately than near-term operational news. FY2030 Earnings Forecast for Arcellx Issued By HC Wainwright
• Neutral Sentiment: Market commentary pieces (example: “Is It Too Late To Consider Arcellx…”) are evaluating the recent run-up and valuation; these are background reads that may sway retail interest but do not constitute new company fundamentals. Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge?
• Negative Sentiment: Insider selling: Director Rami Elghandour sold 89,916 shares at ~$113.92 (≈$10.24M), cutting his stake by ~24.6%. Large insider sales at current levels can weigh on sentiment, especially after a recent price run. SEC Filing
• Negative Sentiment: Quarterly results: ACLX reported EPS of ($1.01), matching consensus, but revenue was $1.65M vs. expectations of $13.4M — a sizable revenue shortfall that highlights execution or timing risk and likely increases near-term volatility and downside pressure.
• Negative Sentiment: Analyst actions: UBS downgraded the stock, and both Robert W. Baird and Canaccord Genuity moved ACLX to “Hold” — multiple downward analyst moves reduce buy-side momentum and can trigger short-term selling. UBS downgrades Arcellx (ACLX) Cut to Hold at Robert W. Baird Cut to Hold at Canaccord Genuity Group

Institutional Trading of Arcellx

Several large investors have recently added to or reduced their stakes in the stock. Schroder Investment Management Group purchased a new position in shares of Arcellx during the second quarter valued at about $3,951,000. Monaco Asset Management SAM bought a new stake in Arcellx during the 3rd quarter valued at approximately $6,452,000. Pathway Capital Management LP bought a new stake in Arcellx during the 3rd quarter valued at approximately $4,191,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Arcellx during the 3rd quarter worth approximately $1,273,000. Finally, American Century Companies Inc. raised its position in shares of Arcellx by 694.3% in the 2nd quarter. American Century Companies Inc. now owns 431,466 shares of the company’s stock worth $28,412,000 after acquiring an additional 377,145 shares in the last quarter. Institutional investors own 96.03% of the company’s stock.

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.